Measuring the effects of continuous dopaminergic stimulation on nocturnal movements in Parkinson's disease.

Measuring the effects of continuous dopaminergic stimulation on nocturnal movements in Parkinson's disease. - Nocturnal movements and rotigotine in Parkinson's disease

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON35536

Enrollment

Registered

2012-02-27

Start date

2012-05-09

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

difficulty turning around in bed nocturnal hypokinesia

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with idiopathic PD Patients who will start treatment with rotigotine Hoehn & Yahr stage II - IV Subjective sleep problems most likely caused by nocturnal hypokinesia

Exclusion criteria

Exclusion criteria: Other significant causes for nocturnal motor symptoms which are not dopamine-responsive Previous surgery for PD Mini- mental state examination score

Design outcomes

Primary

Measure	Time frame
Position changes over the night.	—

Secondary

Measure	Time frame
Objective • Degree of mobility, measured as the speed of the movements • Total amount of movements • Score on the motor symptom scale according to the MDS-UPDRS part III Subjective • Nocturnal sleep quality Excessive daytime sleepiness • Presence of nocturnal akinesia	—

Countries

Netherlands

Outcome results